A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy Adults

NCT06173011 | Unknown Phase 1

• 1 other identifier: QL2107-101
• Study Type: interventional
• Target: 168
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to compare the pharmacokinetic and safety similarity of QL2107 with Keytruda® marketed in China and the United States in healthy male volunteers. Participants will receive a single injection of QL2107/ Keytruda® （China）/Keytruda® （US）.Researchers will compare pharmacokinetic, safety, and immunogenic similarities between the three groups.

Conditions

Tumor

Outcome Measures

Primary Outcomes (1)

• AUC0-∞

  To evaluate pharmacokinetic similarity between QL2107 and Keytruda® (china/US)after a single intravenous infusion in healthy volunteers

  113day

Secondary Outcomes (8)

• safety and immunogenicity

  113day

• Cmax

  113day

• Tmax

  113day

• AUC0-t

  113day

• t1/2

  113day

Study Arms (3)

QL2107

EXPERIMENTAL

QL2107, intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)

Drug: QL2107

Keytruda®(china)

ACTIVE COMPARATOR

Keytruda® (china), intravenously infusion 35 min (±5min, at least 30min), D1 (Day 1, single dose);

Drug: Keytruda®(china)

Keytruda®(US)

ACTIVE COMPARATOR

Keytruda® (US), intravenously infusion 35 min (±5min, at least 30min), D1 (Day 1, single dose);

Drug: Keytruda®(US)

Interventions

QL2107 DRUG

intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)

QL2107

Keytruda®(china) DRUG

intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)

Keytruda®(china)

Keytruda®(US) DRUG

intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)

Keytruda®(US)

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Sign the informed consent form and fully understand the test content, process and possible adverse reactions, and be able to complete the study according to the test plan requirements;
• Age 18 \~ 50 (inclusive) years , male;
• kg≤ body weight ≤90.0 kg and 18.0 kg/m2≤ Body mass index (BMI) ≤28.0 kg/m2;
• Agree to use effective contraception throughout the study period (including but not limited to: physical contraception, surgery, abstinence, etc.) until at least 6 months after the study dosing;
• No history of disease or abnormal past medical history is not clinically significant, and the study doctor's judgment has no impact on the trial.

You may not qualify if:

• \. Clinical laboratory examination, infectious disease screening, chest orthogram examination, abdominal color ultrasound examination, 12-lead electrocardiogram, heart color ultrasound, physical examination, vital signs (systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg) the abnormalities in each examination have clinical significance or are determined to have an impact on the trial (subject to the judgment of the clinical study physician);
• (2) Have been or are currently suffering from any clinically serious disease of the circulatory system, endocrine system, nervous system, digestive system, respiratory system, urogenital system, hematology, immunology, psychiatric and metabolic abnormalities, or any other disease that can interfere with the test results;
• \. Presence of any active autoimmune disease or history of autoimmune disease (including but not limited to: rheumatoid arthritis, ankylosing spondylitis, autoimmune hemolytic anemia, interstitial pneumonia, uveitis, inflammatory bowel disease, autoimmune hepatitis, autoimmune pituitaritis, glomerulonephritis, hyperthyroidism or hypothyroidism, etc.)
• \. Known history of tuberculosis or suspected clinical manifestations of tuberculosis (including but not limited to tuberculosis, lymphatic tuberculosis, tuberculous pleurisy, etc.);
• \. Patients with a history of acute infection within 2 weeks before screening;
• \. There have been herpes zoster virus infections within 3 months before screening;
• \. Viral hepatitis (including hepatitis B and C), AIDS antibody, treponema pallidum antibody screening positive;
• \. Allergies (multiple drug and food allergies), who were determined by the researcher to be unable to participate in this study;
• \. Patients who had surgery within 4 weeks prior to screening or planned to have surgery during the study period;
• \. Those who have used any biological product or received live viral vaccine (tetanus toxoid vaccine within 1 year before infusion), used any monoclonal antibody within 6 months or 5 biological half-lives of drug metabolism, or used PD-1/PD-L1 drugs in the past;
• \. Those who have used any drug or health product (including Chinese herbal medicine) within 14 days prior to the infusion of the experimental drug;
• \. Participants who participated in any clinical trial and used any clinical trial drug within 3 months prior to screening;
• \. Study patients who donated blood or lost a large amount of blood (\> 400 mL) or received blood transfusions or used blood products within 3 months prior to administration;
• \. Smokers or smokers who smoked more than 5 cigarettes per day in the 3 months prior to screening or who could not stop using any tobacco products during the trial;
• \. Positive drug screening or/and alcohol breath test screening prior to study administration;

Sponsors & Collaborators

• Qilu Pharmaceutical Co., Ltd.: lead

Study Sites (1)

The First Affiliated Hospital of Jilin University

Changchun, Jilin, 130000, China

RECRUITING

MeSH Terms

Conditions

Neoplasms

Central Study Contacts

yanhua ding

CONTACT

0431-88782168; dingyanhua2003@126.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 29, 2023
• First Posted: December 15, 2023
• Study Start: December 12, 2023
• Primary Completion: July 1, 2024
• Study Completion: July 1, 2024
• Last Updated: January 23, 2024

Record last verified: 2023-11

Locations

CN (1)